The growing demand for weight control treatments has been driving new care models in the healthcare sector. In this scenario, Vauti Saúde is betting on the combination of technology, medicine, and individualized monitoring to structure a weight loss journey carried out remotely, ranging from initial assessment to support during treatment.
In recent years, medications based on semaglutide and tirzepatide have gained ground in obesity treatment and become popularly known as "pens." These substances are administered subcutaneously and act on mechanisms related to satiety and appetite regulation, showing significant weight reduction results in clinical studies.
Tirzepatide has stood out for the results observed in recent research, while semaglutide has become established among the therapies used for managing excess weight. However, the use of these medications depends on medical indication, and the choice of therapy, doses, and continuation of treatment must be defined by health professionals.
